Cargando…

Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa

The South African national combination antiretroviral therapy (cART) roll-out program started in 2006, with over 4.4 million people accessing treatment since it was first introduced. HIV-1 drug resistance can hamper the success of cART. This study determined the patterns of HIV-1 drug-resistance ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Obasa, Adetayo Emmanuel, Mikasi, Sello Given, Brado, Dominik, Cloete, Ruben, Singh, Kamlendra, Neogi, Ujjwal, Jacobs, Graeme Brendon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099763/ https://www.ncbi.nlm.nih.gov/pubmed/32265875 http://dx.doi.org/10.3389/fmicb.2020.00438

Ejemplares similares

Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding
por: Chitongo, Rumbidzai, et al.
Publicado: (2020)

Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors
por: Isaacs, Darren, et al.
Publicado: (2020)

Correction: Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding
por: Chitongo, Rumbidzai, et al.
Publicado: (2020)

Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa
por: Brado, Dominik, et al.
Publicado: (2018)

Author Correction: Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa
por: Brado, Dominik, et al.
Publicado: (2018)

Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa
por: Obasa, Adetayo Emmanuel, et al.
Publicado: (2021)

Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
por: Mikasi, Sello Given, et al.
Publicado: (2021)

Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes
por: Rogers, Leonard, et al.
Publicado: (2018)

MiDRMpol: A High-Throughput Multiplexed Amplicon Sequencing Workflow to Quantify HIV-1 Drug Resistance Mutations against Protease, Reverse Transcriptase, and Integrase Inhibitors
por: Aralaguppe, Shambhu G., et al.
Publicado: (2019)

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
por: Rhee, Soo-Yon, et al.
Publicado: (2016)

Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
por: Winters, Mark A., et al.
Publicado: (2012)

Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
por: Scherrer, Alexandra U., et al.
Publicado: (2012)

Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq
por: Dudley, Dawn M, et al.
Publicado: (2014)

Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
por: Scherrer, Alexandra U., et al.
Publicado: (2013)

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
por: Smith, Steven J., et al.
Publicado: (2014)

Near full-length HIV-1 subtype B sequences from the early South African epidemic, detecting a BD unique recombinant form (URF) from a sample in 1985
por: Obasa, Adetayo Emmanuel, et al.
Publicado: (2019)

Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors
por: Nathan, Bavithra, et al.
Publicado: (2013)

Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada
por: Bourgi, Kassem, et al.
Publicado: (2020)

Coevolved Multidrug-Resistant HIV-1 Protease and Reverse Transcriptase Influences Integrase Drug Susceptibility and Replication Fitness
por: Martin, Supang A., et al.
Publicado: (2021)

Affordable drug resistance genotyping of HIV-1 reverse transcriptase, protease and integrase genes, for resource limited settings
por: Manyana, Sontaga, et al.
Publicado: (2023)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
por: Himmel, Daniel M., et al.
Publicado: (2020)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens
por: López-Cortés, Luis F., et al.
Publicado: (2016)

Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors
por: Chen, Yen-Wen, et al.
Publicado: (2020)

The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany
por: Mahlich, Jörg, et al.
Publicado: (2016)

A Partially Multiplexed HIV Drug Resistance (HIVDR) Assay for Monitoring HIVDR Mutations of the Protease, Reverse-Transcriptase (PRRT), and Integrase (INT)
por: DeVos, Joshua, et al.
Publicado: (2022)

Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitors
por: Barber, Tristan J, et al.
Publicado: (2014)

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
por: Taramasso, Lucia, et al.
Publicado: (2018)

Viral Protease Inhibitors
por: Anderson, Jeffrey, et al.
Publicado: (2009)

Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
por: Hamada, Yohei, et al.
Publicado: (2013)

Dual therapy based on raltegravir and boosted protease inhibitors – the experience of Polish centers
por: Jabłonowska, Elżbieta, et al.
Publicado: (2016)

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
por: Manasa, Justen, et al.
Publicado: (2017)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
por: Siedner, Mark J., et al.
Publicado: (2020)

The prototype foamy virus protease is active independently of the integrase domain
por: Spannaus, Ralf, et al.
Publicado: (2012)

A study of proteases and protease-inhibitor complexes in biological fluids
por: Granelli-Piperno, A, et al.
Publicado: (1978)

Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process
por: Adamson, Catherine S.
Publicado: (2012)

Proteases and Protease Inhibitors of Urinary Extracellular Vesicles in Diabetic Nephropathy
por: Musante, Luca, et al.
Publicado: (2015)

Identification of Proteases and Protease Inhibitors in Allergenic and Non-Allergenic Pollen
por: Höllbacher, Barbara, et al.
Publicado: (2017)

Fingerprinting of Proteases, Protease Inhibitors and Indigenous Peptides in Human Milk
por: Thesbjerg, Martin Nørmark, et al.
Publicado: (2023)

Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings
por: Lima, Viviane D, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v7nn1nah9cllnh65ap9k8qgg2j